Download PDF
Drug Res (Stuttg)
DOI: 10.1055/a-2567-9916
Original Article

Enhancing Doxorubicin Sensitivity in Osteosarcoma Cancer Cells: Unveiling the Role of Resveratrol-Induced Oxidative DNA Damage

Mohammad Reza Bazavar
1   Department of Orthopedic Surgery, School of Medicine and Shohada Educational Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
,
Hamed Helali
1   Department of Orthopedic Surgery, School of Medicine and Shohada Educational Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
,
Linda Mohammadzadeh Boukani
2   Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
,
Bahman Yousefi 
2   Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3   Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
,
Amir Valizadeh 
2   Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3   Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction

Our current research aims to investigate how Resveratrol influences DOX-induced apoptosis in Saos-2 cells resulting from DNA damage.

Methods

Saos-2 cells were cultured with DOX, and an MTT assay was conducted to evaluate cell viability. The expression levels of DNA damage markers were evaluated using qRT-PCR and western blotting methods. Apoptosis was also investigated by flow cytometry.

Results

In a dose-dependent way, DOX produced a profuse suppression of cell proliferation. This study investigates the effect of Resveratrol on DOX-induced apoptosis due to DNA damage in Saos-2 cells (P<0.05). There was an increase in H2AX, ATR, ATM, Rad51, and p53 expression, possibly contributing to subsequent apoptosis. Furthermore, Resv enhanced the apoptosis caused by DOX in Saos-2 cells.

Conclusion

The findings from the current research provide an understanding of how Resv plays a role in potentially treating osteosarcoma by enhancing DOX-induced apoptosis.

Keywords

pharmacology - drug research - chemical biology


Publication History

Received: 23 January 2025

Accepted: 24 March 2025

Article published online:
24 April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 2021; 18: 609-624
    PubMedSearch in Google Scholar
  • 2 Eaton BR, Schwarz R, Vatner R. et al. Osteosarcoma. Pediatr Blood Cancer 2021; 68: e28352
    PubMedSearch in Google Scholar
  • 3 Wu C, Gong S, Duan Y. et al. A tumor microenvironment-based prognostic index for osteosarcoma. J Biomed Sci 2023; 30: 23
    PubMedSearch in Google Scholar
  • 4 Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med 2021; 385: 2066-2076
    PubMedSearch in Google Scholar
  • 5 Abdelrahman S, Ireland A, Winter EM. et al. Osteoporosis after spinal cord injury: aetiology, effects and therapeutic approaches. J Musculoskelet Neuronal Interact 2021; 21: 26-50
    PubMedSearch in Google Scholar
  • 6 Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci 2020; 21: 9
    PubMedSearch in Google Scholar
  • 7 Wei G, Wang Y, Yang G. et al. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021; 11: 6370-6392
    PubMedSearch in Google Scholar
  • 8 Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 2019; 53: 148-158
    CrossrefPubMedSearch in Google Scholar
  • 9 Behranvand N, Nasri F, Zolfaghari Emameh R. et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother 2022; 71: 507-526
    PubMedSearch in Google Scholar
  • 10 Benjamin RS. Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective. Adv Exp Med Biol 2020; 1257: 1-10
    PubMedSearch in Google Scholar
  • 11 Kciuk M, Gielecińska A, Mujwar S. et al. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells 2023; 12: 4
    PubMedSearch in Google Scholar
  • 12 Mattioli R, Ilari A, Colotti B. et al. Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming. Molecular Aspects of Medicine 2023; 93: 101205
    PubMedSearch in Google Scholar
  • 13 Kursvietiene L, Kopustinskiene DM, Staneviciene I. et al Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions. Antioxidants (Basel) 2023; 12 12
    PubMedSearch in Google Scholar
  • 14 Han Y, Jo H, Cho JH. et al. Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer. Int J Mol Sci 2019; 20: 4
    PubMedSearch in Google Scholar
  • 15 Ko JH, Sethi G, Um JY. et al. The Role of Resveratrol in Cancer Therapy. Int J Mol Sci 2017; 18: 12
    PubMedSearch in Google Scholar
  • 16 Roshani M, Jafari A, Loghman A. et al. Applications of resveratrol in the treatment of gastrointestinal cancer. Biomed Pharmacother 2022; 153: 113274
    PubMedSearch in Google Scholar
  • 17 Holohan C, Van Schaeybroeck S, Longley DB. et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726
    CrossrefPubMedSearch in Google Scholar
  • 18 Perrone D, Fuggetta MP, Ardito F. et al. Resveratrol (3,5,4'-trihydroxystilbene) and its properties in oral diseases. Exp Ther Med 2017; 14: 3-9
    PubMedSearch in Google Scholar
  • 19 Fabre KM, Saito K, DeGraff W. et al. The effects of resveratrol and selected metabolites on the radiation and antioxidant response. Cancer Biol Ther 2011; 12: 915-923
    PubMedSearch in Google Scholar
  • 20 Choi CY, Lim SC, Lee TB. et al. Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells. Nutrients 2022; 14: 3
    PubMedSearch in Google Scholar
  • 21 Gupta SC, Kannappan R, Reuter S. et al. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011; 1215: 150-160
    PubMedSearch in Google Scholar
  • 22 Tiek D, Cheng SY. DNA damage and metabolic mechanisms of cancer drug resistance. Cancer Drug Resist 2022; 5: 368-379
    PubMedSearch in Google Scholar
  • 23 Kim TH, Shin YJ, Won AJ. et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 2014; 1840: 615-625
    PubMedSearch in Google Scholar
  • 24 Brockmueller A, Sajeev A, Koklesova L. et al. Resveratrol as sensitizer in colorectal cancer plasticity. Cancer Metastasis Rev 2023; 43: 55-85
    PubMedSearch in Google Scholar
  • 25 Leon-Galicia I, Diaz-Chavez J, Albino-Sanchez ME. et al. Resveratrol decreases Rad51 expression and sensitizes cisplatin‑resistant MCF‑7 breast cancer cells. Oncol Rep 2018; 39: 3025-3033
    PubMedSearch in Google Scholar